"目录号: HY-14728 ee.: 99.75%
Aleglitazar(R1439; RO-0728804)是PPAR-α/γ激动剂，IC50分别为2.8 nM/4.6 nM。
相关产品
GW9662-Rosiglitazone-Retinoic acid-Troglitazone-Pioglitazone hydrochloride-Elafibranor-GW 501516-CDDO-Im-Fenofibrate-T0070907-Wy-14643-GW0742-Daidzein-FH535-BMS-687453-
生物活性
Description
Aleglitazar(R1439; RO-0728804) is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM.IC50 Value: 2.8 nM(PPAR-α); 4.6 nM(PPAR-γ)Target: PPARα/γAleglitazar (R1439) is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPARα and PPARγ. Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones.
Clinical Trial
Hoffmann-La Roche
Healthy Volunteer
September 2010
Phase 1
Hoffmann-La Roche
Healthy Volunteer
October 2012
Phase 1
Hoffmann-La Roche
Healthy Volunteer
August 2012
Phase 1
Hoffmann-La Roche
Healthy Volunteer
November 2012
Phase 1
Hoffmann-La Roche
Diabetes Mellitus Type 2
May 2010
Phase 2
Hoffmann-La Roche
Diabetes Mellitus Type 2
February 2010
Phase 3
Hoffmann-La Roche
Diabetes Mellitus Type 2
June 2013
Phase 3
Hoffmann-La Roche
Cardiovascular Disease, Diabetes Mellitus Type 2
December 2012
Phase 3
Hoffmann-La Roche
Diabetes Mellitus Type 2
October 2012
Phase 3
Hoffmann-La Roche
Healthy Volunteer
June 2010
Phase 1
Hoffmann-La Roche
Healthy Volunteer
July 2010
Phase 1
Hoffmann-La Roche
Diabetes Mellitus Type 2
June 2007
Phase 2
Hoffmann-La Roche
Diabetes Mellitus Type 2
November 2012
Phase 3
Hoffmann-La Roche
Diabetes Mellitus Type 2
May 2007
Phase 2
Hoffmann-La Roche
Diabetes Mellitus Type 2
December 2012
Phase 3
Hoffmann-La Roche
Diabetes Mellitus Type 2
May 2013
Phase 3
Hoffmann-La Roche
Diabetes Mellitus Type 2
October 2012
Phase 2
Hoffmann-La Roche
Diabetes Mellitus Type 2
December 2012
Phase 2
Hoffmann-La Roche
Diabetes Mellitus Type 2
August 2011
Phase 1
Hoffmann-La Roche
Diabetes Mellitus Type 2
November 2006
Phase 2
Hoffmann-La Roche
Diabetes Mellitus Type 2, Kidney Disease, Chronic
December 2013
Phase 3
Hoffmann-La Roche
Healthy Volunteer
July 2012
Phase 1
Hoffmann-La Roche
Healthy Volunteer
September 2010
Phase 1
Hoffmann-La Roche
Healthy Volunteer
October 2012
Phase 1
Hoffmann-La Roche
Healthy Volunteer
August 2012
Phase 1
Hoffmann-La Roche
Healthy Volunteer
November 2012
Phase 1
Hoffmann-La Roche
Diabetes Mellitus Type 2
May 2010
Phase 2
Hoffmann-La Roche
Diabetes Mellitus Type 2
February 2010
Phase 3
Hoffmann-La Roche
Diabetes Mellitus Type 2
June 2013
Phase 3
Hoffmann-La Roche
Cardiovascular Disease, Diabetes Mellitus Type 2
December 2012
Phase 3
Hoffmann-La Roche
Diabetes Mellitus Type 2
October 2012
Phase 3
Hoffmann-La Roche
Healthy Volunteer
June 2010
Phase 1
Hoffmann-La Roche
Healthy Volunteer
July 2010
Phase 1
Hoffmann-La Roche
Diabetes Mellitus Type 2
June 2007
Phase 2
Hoffmann-La Roche
Diabetes Mellitus Type 2
November 2012
Phase 3
Hoffmann-La Roche
Diabetes Mellitus Type 2
May 2007
Phase 2
Hoffmann-La Roche
Diabetes Mellitus Type 2
December 2012
Phase 3
Hoffmann-La Roche
Diabetes Mellitus Type 2
May 2013
Phase 3
Hoffmann-La Roche
Diabetes Mellitus Type 2
October 2012
Phase 2
Hoffmann-La Roche
Diabetes Mellitus Type 2
December 2012
Phase 2
Hoffmann-La Roche
Diabetes Mellitus Type 2
August 2011
Phase 1
Hoffmann-La Roche
Diabetes Mellitus Type 2
November 2006
Phase 2
Hoffmann-La Roche
Diabetes Mellitus Type 2, Kidney Disease, Chronic
December 2013
Phase 3
Hoffmann-La Roche
Healthy Volunteer
July 2012
Phase 1
View MoreCollapse
References
